Dana-Farber Cancer Institute Study on Ignite Proteomics’ RPPA Platform for T-DXd Therapy in Breast Cancer Patients
Aditxt, Inc. announced that its precision oncology subsidiary, Ignite Proteomics, was featured in a study published in npj Precision Oncology, evaluating the predictive value of its RPPA platform for T-DXd therapy in metastatic breast cancer patients. The research was led by investigators from Dana-Farber Cancer Institute.
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patien